A Milestone Achievement in Hemophilia Care

In an unprecedented move, the World Federation of Hemophilia (WFH) and its global allies have successfully prompted the World Health Organization (WHO) to revise its Essential Medicines List (EML) and the Essentials for Children (EMLc). This groundbreaking update ensures that the therapies for hemophilia and von Willebrand Disease (VWD) now align with the latest international clinical standards—bringing newfound hope to patients worldwide.

Impacting Lives: The Power of Updated Guidelines

The WHO EML serves as a crucial framework for nations, guiding them in the selection and funding of essential medicines. With these updates, policymakers can now make informed decisions that directly affect the lives of those suffering from bleeding disorders. "This update is a beacon of hope for thousands of people with bleeding disorders, bringing our vision of 'Treatment for All' closer to reality," remarked Cesar Garrido, President of WFH.

Key Changes in the Essential Medicines List

The recent updates introduced in the latest 24th EML and 10th EMLc include significant changes aimed at enhancing treatment options: - **New Additions**: The life-saving bi-specific monoclonal antibody, emicizumab, and recombinant FVIII and FIX clotting factor concentrates have been added to the core list, marking a new era in treatment. - **Revised Listings**: Plasma-derived FVIII and FIX CFCs, previously on the complementary list, are now included in the core list, along with desmopressin. - **Removals**: Alarmingly, both pathogen-reduced and non-pathogen reduced cryoprecipitate have been removed from treatment options due to their risks associated with bloodborne infections, highlighting a clear shift toward safer alternatives.

Collaboration is Key

This monumental achievement was realized through an extensive two-year collaboration involving the WFH, the WHO, and numerous experts from around the globe. Dr. Glenn Pierce, Vice President of Medical at WFH, emphasized, "This decision ensures modern, effective treatments reach those who need them most. The strong support from patient advocacy groups and scientific organizations worldwide has made this possible. Together, we've reshaped global policy to align with the best clinical practices."

A Unified Front for Change

The WFH extends gratitude to its national member organizations, expert clinicians, and advocacy groups for their unwavering support in this vital initiative. The advocacy campaign saw endorsements from 115 WFH member organizations and more than 120 expert clinicians across various regions, showcasing a collaborative spirit in the quest for better care. Organizations like the European Haemophilia Consortium and the International Society on Thrombosis and Haemostasis played pivotal roles in this transformation.

What Lies Ahead?

With the WHO's updated EML now official, the WFH's vision of accessible treatment for all is closer than ever. The commitment to global health equity is now stronger, ensuring that every individual affected by bleeding disorders has a fair chance at effective treatment. This is not just a victory for the WFH but for the countless families and individuals striving for better health.

Understanding Hemophilia

Hemophilia and similar disorders can severely disrupt the blood clotting process, leading to prolonged bleeding and significant health risks. Timely access to appropriate treatments is crucial to prevent devastating complications.

Join the Movement

For those who want to contribute to this noble cause or learn more about the WFH's mission, visit www.wfh.org. Together, let’s continue the fight for a world where every person with an inherited bleeding disorder can receive the treatment they deserve.